A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

Description

The objective of this study is to assess safety and efficacy of BA3071 in solid tumors

Conditions

NSCLC, Melanoma

Talk to us

Study Overview

On this page

Study Details

Study overview

The objective of this study is to assess safety and efficacy of BA3071 in solid tumors

A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

Condition
NSCLC
Intervention / Treatment

-

Contacts and Locations

Los Angeles

The Angeles Clinic and Research Institute, Los Angeles, California, United States, 90025

Los Angeles

USC Norris Comprehensive Cancer Center, Los Angeles, California, United States, 90033

Atlanta

Piedmont West, Atlanta, Georgia, United States, 30318

Dyer

Northwest Cancer Centers, Dyer, Indiana, United States, 46311

Morristown

Morristown Medical Center/Atlantic Health System, Morristown, New Jersey, United States, 07960

New York

Icahn School of Medicine at Mt. Sinai, New York, New York, United States, 10029

Cleveland

University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States, 44106

Portland

Providence Cancer Institute, Portland, Oregon, United States, 97213

Salt Lake City

University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States, 84112

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients must have measurable disease.
  • * Age ≥ 18 years
  • * CLTA-4 blocking-antibody naïve
  • * Adequate renal function
  • * Adequate liver function
  • * Adequate hematological function
  • * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • * Patients must have single or any combination of the following mutations: KRAS, STK11, KEAP1 and/or PD-L1 TPS \<1%
  • * Patients must be eligible for surgery (NSCLC Stage IIB-IIIA only)
  • * Patients must not have clinically significant cardiac disease.
  • * Patients must not have known non-controlled CNS metastasis.
  • * Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as well as known or suspected allergy or intolerance to any agent given during this study.
  • * Patients must not have had major surgery within 4 weeks before first BA3071 administration.
  • * Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
  • * Patients must not be women who are pregnant or breast feeding.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

BioAtla, Inc.,

Study Record Dates

2026-06-30